VICTORIA, BC, Oct. 27, 2020 /CNW/ - IMMUNOPRECISE
ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF)
(FSE:TQB2), a leader in full-service, therapeutic antibody
discovery and development, today announced that its subsidiary,
Talem Therapeutics, entered into a collaboration with Twist
Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, to leverage the unique strengths of
both companies' technologies in the creation of novel, therapeutic
molecules.
By entering this early discovery collaboration with Twist, Talem
will be expanding its diverse antibody pipeline by exploring IPA's
technology on a wider range of oncology targets, combining their
expertise in a highly collaborative manner to discover novel
antibody therapeutics. ImmunoPrecise will contribute targets of
interest with relevant background data, and the genetic sequences
encoding for lead antibodies against the selected targets. Twist
Biopharma, a division of Twist Bioscience, will design
synthetic antibody libraries based on the provided antibody
repertoire sequences from immunized animals to discover optimized,
humanized lead antibody candidates. The companies will then aim to
jointly advance the programs through proof-of-concept and
preclinical development and will collaborate on any commercial
opportunities generated by these joint efforts which may result in
milestones based on key preclinical, clinical and commercial
milestones as well as royalties for any antibodies resulting from
the collaboration.
"Our collaboration with Twist recognizes the potential
of their well-established ability to create precision antibody
discovery libraries, enabling us to further expedite our
pre-clinical development through collaboration," said Dr.
Jennifer Bath, CEO
of ImmunoPrecise Antibodies. "We look forward to working
closely with Twist to pioneer the discovery and
development of new, cutting-edge cancer treatments."
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a global technology platform company with
end-to-end solutions empowering companies to discover and develop
therapies against any disease. The Company's experience and
cutting-edge technologies enable unparalleled support of its
partners in their quest to bring innovative treatments to the
clinic. ImmunoPrecise's full-service capabilities dramatically
reduce the time required for, and the inherent risk associated
with, conventional multi-vendor product development. For further
information, visit www.immunoprecise.com or contact
solutions@immunoprecise.com.
Forward Looking Information
This news release contains statements that, to the extent
they are not recitations of historical fact, may constitute
"forward-looking statements" within the meaning of applicable
Canadian securities laws. The Company uses words such as "may",
"would", "could", "will", "likely", "expect", "believe", "intend",
"should" and similar expressions to identify forward-looking
statements. Any such forward-looking statements are based on
assumptions and analyses made by ImmunoPrecise in light of its
experience and its perception of historical trends, current
conditions and expected future developments. However, whether
actual results and developments will conform to ImmunoPrecise's
expectations and predictions is subject to any number of risks,
assumptions and uncertainties. Many factors could cause
ImmunoPrecise's actual results to differ materially from those
expressed or implied by the forward-looking statements contained in
this news release. Such factors include, among other things, actual
revenues and earnings for IPA being lower than anticipated, and
those risks and uncertainties described in ImmunoPrecise's annual
management discussion and analysis for the previous quarter ended
July 31st, 2020 which can
be accessed at www.sedar.com. The "forward-looking
statements" contained herein speak only as of the date of this
press release and, unless required by applicable law, ImmunoPrecise
undertakes no obligation to publicly update or revise such
information, whether as a result of new information, future events
or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/immunoprecise-and-twist-bioscience-announce-collaboration-for-the-creation-of-novel-therapeutic-products-301160372.html
SOURCE ImmunoPrecise Antibodies Ltd.